Colorectal Disorders
Conditions
Brief summary
The purpose of this study is to determine if an intravenous lidocaine infusion (compared to placebo) intraoperatively will decrease time to return of bowel function postoperatively, decrease postoperative pain, diminish postoperative opioid requirement, minimize inflammatory markers and shorten time to discharge after colorectal surgery.
Detailed description
Lidocaine is an amide local anesthetic that has analgesic and anti-inflammatory properties. Lidocaine infusion is a very useful pain medication that is underutilized to treat surgical, chronic, and cancer pain in children. The investigators propose to examine the perioperative use of lidocaine infusion in children undergoing colorectal surgery that involves an abdominal incision. The investigators plan to measure the following outcomes: length of stay in hospital following abdominal surgery, postoperative pain scores, cumulative morphine consumption, incidences of opioid adverse-effects: respiratory depression, sedation, nausea, vomiting, time to passage of flatus, time to first bowel movement and end-tidal Sevoflurane in operating room throughout surgery. The following laboratory values will be measured: serial lidocaine levels of pharmacokinetics and safety levels, Pro- and anti-inflammatory cytokine measurements: IL-6, IL-8, IL-10, IL-1RA and genetic variants.
Interventions
DRUGLidocaine
The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
Sponsors
Children's Hospital Medical Center, Cincinnati
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
1 Years to 15 Years
Healthy volunteers
No
Inclusion criteria
* male or female children 1-15 years of age * ASA physical status 1-3 * scheduled for colorectal surgery with abdominal incision * scheduled for complex urology surgical case
Exclusion criteria
* ASA physical status \> 3 * postoperative intubation planned ahead of surgery * history of chronic use of opioid * history of hepatic,renal, or cardiac failure * history of organ transplant * BMI \> 30 * history of cardiac arrhythmia * history of long QT syndrome * history of allergic reaction to lidocaine or similar agents * history of seizure disorder * patient without Peripherally Inserted Central Catheter or other central access with contraindication to inhalation induction * family history or know patient susceptibility to malignant hyperthermia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Length of stay in hospital following abdominal surgery | participants will be followed for the duration of hospital stay, an average of 1 week | The primary outcome measure will be to monitor the length of stay in hospital following abdominal surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative morphine consumption | participants will be followed post-op, average 5 days | Staff will document how much morphine a patient uses post-operatively after abdominal surgery. |
| Incidences of opioid adverse-effects | participants will be followed post-op, average 5 days | Study staff will monitor nursing notes for respiratory depression, sedation, nausea and vomiting |
| Time to passage of flatus and bowel movement | participants will be followed post-op, average 5 days | Study staff will review nursing notes for time of passage of flatus and first bowel movement. |
| Postoperative pain scores | participants will be followed post-op, average 5 days | Study staff will monitor patients pain every 15 minutes in the PACU and record documentation every 4 hours while on the floor. |
| Serial lidocaine levels for pharmacokinetics and safety levels | participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively | 2 samples will be drawn at time of baseline IV placement Blood draw 0-3 minutes after bolus is complete Blood draw 9-15 minutes after the bolus is complete 2 blood samples will be drawn at the end of continuous infusion (either at end of surgery after extubation prior to leaving OR or after 5 hours from the start of the infusion) Blood draw 1 hour following the infusion Blood draw 2-3 hours following the end of the infusion 2 blood samples will be drawn 24 hours after surgery dependent of necessary labs |
| Pro- and anti-inflammatory cytokine measurements: IL-6, IL-8, IL-10, IL-1RA | participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively | 2 samples will be drawn at time of baseline IV placement Blood draw 0-3 minutes after bolus is complete Blood draw 9-15 minutes after the bolus is complete 2 blood samples will be drawn at the end of continuous infusion (either at end of surgery after extubation prior to leaving OR or after 5 hours from the start of the infusion) Blood draw 1 hour following the infusion Blood draw 2-3 hours following the end of the infusion 2 blood samples will be drawn 24 hours after surgery dependent of necessary labs |
| Genetic variants | participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively | 2 samples will be drawn at time of baseline IV placement Blood draw 0-3 minutes after bolus is complete Blood draw 9-15 minutes after the bolus is complete 2 blood samples will be drawn at the end of continuous infusion (either at end of surgery after extubation prior to leaving OR or after 5 hours from the start of the infusion) Blood draw 1 hour following the infusion Blood draw 2-3 hours following the end of the infusion 2 blood samples will be drawn 24 hours after surgery dependent of necessary labs |
| End-tidal Sevoflurane in operating room throughout surgery | participants will be measured until the end of the OR case, on average 6 hours | — |
Countries
United States
Outcome results
None listed